Intellia Therapeutics (NTLA) Capital Expenditures (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Capital Expenditures for 11 consecutive years, with $126000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Capital Expenditures fell 37.93% year-over-year to $126000.0; the TTM figure through Mar 2026 stood at $1.0 million (up 156.69% YoY), while the FY2025 annual figure was $1.1 million, up 95.67% from the prior year.
• Capital Expenditures fell to $126000.0 in Q4 2025 per NTLA's latest filing, from $1.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $4.6 million in Q2 2023 and bottomed at -$10.9 million in Q4 2023.
• Historically, Capital Expenditures has averaged $880500.0 across 5 years, with a median of $552000.0 in 2021.
• On a YoY basis, Capital Expenditures climbed as much as 15789.66% in 2023 and fell as far as 1864.09% in 2023.
• Intellia Therapeutics' Capital Expenditures stood at $2.9 million in 2021, then sank by 119.42% to -$557000.0 in 2022, then tumbled by 1864.09% to -$10.9 million in 2023, then soared by 101.86% to $203000.0 in 2024, then tumbled by 37.93% to $126000.0 in 2025.
• Business Quant data shows NTLA's Capital Expenditures at $126000.0 in Q4 2025, $1.0 million in Q3 2025, and -$82000.0 in Q2 2025.